De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.

被引：0
|
作者：
Goldvaser, Hadar
Yasmin, Korzets Ceder
Shepshelovich, Daniel
Yerushalmi, Rinat
Sarfaty, Michal
Ribnikar, Domen
Thavendiranathan, Paaladinesh
Amir, Eitan
机构：
[1] Beilinson Med Ctr, Davidoff Ctr, Rabin Med Ctr, Kyriat Ono, Israel
[2] Beilinson Hosp 32393 Shem, Petah Tiqwa, Israel
[3] Rabin Med Ctr, Petah Tiqwa, Israel
[4] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel
[5] Davidoff Canc Ctr, Petah Tiqwa, Israel
[6] Princess Margaret Canc Ctr, Toronto, ON, Canada
[7] Toronto Gen Hosp, Res Inst, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.524
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
524
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Anne Julienne Genuino
    Usa Chaikledkaew
    Anna Melissa Guerrero
    Thanyanan Reungwetwattana
    Ammarin Thakkinstian
    BMC Health Services Research, 19
  • [42] Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
    Genuino, Anne Julienne
    Chaikledkaew, Usa
    Guerrero, Anna Melissa
    Reungwetwattana, Thanyanan
    Thakkinstian, Ammarin
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (01)
  • [43] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
  • [44] Cost of managing recurrent human epidermal growth factor receptor 2 (HER2) positive breast cancer in women previously treated for early stage disease in the UK
    Brazil, Lucy
    Remak, Edit
    Poole, Christopher J.
    Muszbek, Noemi
    Cohen, Carole
    Geary, Una
    Walker, Mel
    ANNALS OF ONCOLOGY, 2006, 17 : 82 - 82
  • [45] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Tran, Phuong T.
    Diaby, Vakaramoko
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 221 - 221
  • [46] Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (HALT: LPT112515).
    Lin, Nancy U.
    Danso, Michael A.
    David, Alice K.
    Muscato, Joseph J.
    Rayson, Daniel
    Houck, William A.
    Ellis, Catherine Elizabeth
    DeSilvio, Michelle
    Garofalo, Amanda
    Levin, Jeremy
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Trastuzumab as adjuvant therapy for early breast cancer - The importance of accurate human epidermal growth factor receptor 2 testing
    Hicks, David G.
    Kulkarni, Swati
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2008, 132 (06) : 1008 - 1015
  • [48] Trastuzumab: A Milestone in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
    Dhanushkodi, Manikandan
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (01) : 54 - 56
  • [49] Optimum adjuvant trastuzumab duration for human epidermal growth factor receptor-2 positive breast cancer: a network meta-analysis of randomized trials
    Ma, Ji
    Tang, Xiaofang
    Hu, Qiancheng
    Wang, Qingfeng
    Chen, Ye
    Li, Xiaofen
    Luo, Ting
    Cao, Dan
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (04) : 1628 - +
  • [50] Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer
    Quang A. Le
    Yuna H. Bae
    Jenny H. Kang
    Breast Cancer Research and Treatment, 2016, 159 : 565 - 573
12345